Intervention

Pegylated G-CSF

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions2

Lead sponsors shown2

Clinical trials

2 shown

Minimal Islet Transplant at Diabetes OnsetNCT02505893 · 2015-04-01

COMPLETED

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCNCT01933932 · 2013-09-25

ACTIVE_NOT_RECRUITING

Common conditions

Diabetes Mellitus, Type 11 Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1

Leading sponsors

AstraZeneca1 Ospedale San Raffaele1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

Phase mix

PHASE21

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.